Emflaza 30 MG Oral Tablet

RxCUI: 1870952
RxNorm name: Emflaza 30 MG Oral Tablet
Display name: Emflaza 30 MG Oral Tablet
Full name: Emflaza 30 MG Oral Tablet
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:38:52

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
EMFLAZA	DEFLAZACORT	PTC Therapeutics, Inc.	31b347d2-f156-4055-9d8f-7cf0df420296	2025-11-13	Warnings, Adverse reactions	Exact identifier rxcui: 1870952

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
31b347d2-f156-4055-9d8f-7cf0df420296	Emflaza 30 MG Oral Tablet	SY	21	These highlights do not include all the information needed to use EMFLAZA ® safely and effectively. See full prescribing information for EMFLAZA. EMFLAZA ® (deflazacort) tablets, for oral use EMFLAZA ® (deflazacort) oral suspension Initial U.S. Approval: 2017	20251113
31b347d2-f156-4055-9d8f-7cf0df420296	deflazacort 30 MG Oral Tablet [Emflaza]	SBD	21	These highlights do not include all the information needed to use EMFLAZA ® safely and effectively. See full prescribing information for EMFLAZA. EMFLAZA ® (deflazacort) tablets, for oral use EMFLAZA ® (deflazacort) oral suspension Initial U.S. Approval: 2017	20251113
31b347d2-f156-4055-9d8f-7cf0df420296	Emflaza 30 MG Oral Tablet	PSN	21	These highlights do not include all the information needed to use EMFLAZA ® safely and effectively. See full prescribing information for EMFLAZA. EMFLAZA ® (deflazacort) tablets, for oral use EMFLAZA ® (deflazacort) oral suspension Initial U.S. Approval: 2017	20251113